|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 81 | 2020 | Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies | VAN WIJMEERSCH, Bart; Singer, Barry A.; Boster, Aaron; Broadley, Simon; Fernandez, Oscar; Freedman, Mark S.; Izquierdo, Guillermo; Lycke, Jan; Pozzilli, Carlo; Sharrack, Basil; Steingo, Brian; Wiendl, Heinz; Wray, Sibyl; Ziemssen, Tjalf; Chung, Luke; Margolin, David H.; Thangavelu, Karthinathan; Vermersch, Patrick | Journal Contribution | A1 |
| 82 | 2020 | Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management | Cuker, Adam; Bass, Ann D.; Nadj, Congor; Agius, Mark A.; Steingo, Brian; Selmaj, Krzysztof W.; Thoits, Timothy; Guerreiro, Alexandre; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Meuth, Sven G.; LaGanke, Christopher C.; Thangavelu, Karthinathan; Rodriguez, Claudio E.; Baker, Darren P.; Margolin, David H.; Jannsens, Ann | Journal Contribution | A1 |
| 83 | 2020 | Disability accrual in primary-progressive & secondary-progressive multiple sclerosis | Harding-Forrester, S.; Roos, I.; Sharmin, S; Diouf, I.; Malpas, C.; Nguyen, A. -L.; Moradi, N.; Horakova, D.; Havrdova, E. Kubala; Patti, F.; Izquierdo, G.; Eichau, S.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Weinstock-Guttman, B.; Amato, M. P.; Grammond, P.; Gerlach, O.; Ozakbas, S.; Sola, P.; Ferraro, D.; Butzkueven, H.; Lechner-Scott, J.; Boz, C.; Alroughani, R.; Van Pesch, V.; Cartechini, E.; Terzi, M.; Maimone, D.; Ramo-Tello, C.; Spitaleri, D.; Kappos, L.; Yamout, B.; Sa, M.; Slee, M.; Blanco, Y.; Bergamaschi, R.; Butler, E.; Iuliano, G.; Granella, F.; Sidhom, Y.; Gouider, R.; Ampapa, R.; VAN WIJMEERSCH, Bart; Karabudak, R.; Prevost, J.; Sanchez-Menoyo, J. L.; Verheul, F.; Mccombe, P.; Castillo-Trivino, T.; Macdonell, R.; Altintas, A.; Laureys, G.; Van Hijfte, L.; Van der Walt, A.; Vucic, S.; Turkoglu, R.; Barnett, M.; Cristiano, E.; Zakaria, M.; Shaygannejad, V.; Hodgkinson, S.; Soysal, A.; Kalincik, T. | Journal Contribution | M |
| 84 | 2020 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 85 | 2020 | Comparing 16 Different Dual–Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive-Motor Interference | LEONE, Carmela; MOUMDJIAN, Lousin; Patti, Francesco; VANZEIR, Ellen; BAERT, Ilse; VELDKAMP, Renee; VAN WIJMEERSCH, Bart; FEYS, Peter | Journal Contribution | A1 |
| 86 | 2020 | Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab | Wiendl, Heinz; Carraro, Matthew; Comi, Giancarlo; Izquierdo, Guillermo; Kim, Ho Jin; Sharrack, Basil; Tornatore, Carlo; Daizadeh, Nadia; Chung, Luke; Jacobs, Alan K.; Hogan, Richard J.; Wychowski, Linda V.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 87 | 2020 | Deciphering the Morphology of Motor Evoked Potentials | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M; Dive, D; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 88 | 2020 | The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective | Alroughani, Raed; VAN WIJMEERSCH, Bart; Al Khaboori, Jabber; Alsharoqi, Isa Ahmed; Ahmed, Samar F.; Hassan, Ali; Inshasi, Jihad; Krieger, Derk W.; Shakra, Mustafa; Shatila, Ahmed Osman; Szolics, Miklos; Khallaf, Mohamed; Ezzat, Aly | Journal Contribution | A1 |
| 89 | 2020 | CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis | BOGIE, Jeroen; GRAJCHEN, Elien; WOUTERS, Elien; BROUX, Bieke; STINISSEN, Piet; VAN WIJMEERSCH, Bart; HENDRIKS, Jerome | Journal Contribution | A1 |
| 90 | 2019 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis | Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Onofrj, Marco; Lugaresi, Alessandra; Ozakbas, Serkan; Kappos, Ludwig; Kuhle, Jens; Terzi, Murat; Lechner-Scott, Jeannette; Boz, Cavit; Grand'Maison, Francois; Prevost, Julie; Sola, Patrizia; Ferraro, Diana; Granella, Franco; Trojano, Maria; Bergamaschi, Roberto; Pucci, Eugenio; Turkoglu, Recai; McCombe, Pamela A.; Van Pesch, Vincent; VAN WIJMEERSCH, Bart; Solaro, Claudio; Ramo-Tello, Cristina; Slee, Mark; Alroughani, Raed; Yamout, Bassem; Shaygannejad, Vahid; Spitaleri, Daniele; Luis Sanchez-Menoyo, Jose; Ampapa, Radek; Hodgkinson, Suzanne; Karabudak, Rana; Butler, Ernest; Vucic, Steve; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut | Journal Contribution | A1 |
| 91 | 2019 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis | Meuth, Sven G.; Brandes, David; Carraro, Matthew; Comi, Giancarlo; Mao-Draayer, Yang; Izquierdo, Guillermo; Kim, Ho Jin; Pardo, Gabriel; Sharrack, Basil; Tornatore, Carlo; VAN WIJMEERSCH, Bart; Ziemssen, Tjalf; Jacobs, Alan; Chung, Luke; Daizadeh, Nadia; Wiendl, Heinz | Journal Contribution | M |
| 92 | 2019 | Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) | Pelletier, Daniel; Arnold, Douglas L.; Boyko, Alexey N.; Comi, Giancarlo; Hartung, Hans-Peter; Havrdova, Eva Kubala; Inshasi, Jihad Said; McCombe, Pamela; Nakamura, Kunio; Oreja-Guevara, Celia; Pozzilli, Carlo; Selmaj, Krzysztof W.; Scott, Thomas F.; Chung, Luke; Daizadeh, Nadia; Afsar, Salman; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 93 | 2019 | Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) | Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 94 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
| 95 | 2019 | Neuromyelitis Optica in Flanders: an epidemiological study | Blomme, L.; MOONS, Lynn; Noels, S.; Laureys, G.; VAN WIJMEERSCH, Bart; Crols, R.; DE KLIPPEL, Nina; Van de Velde, K.; Willekens, B. | Journal Contribution | M |
| 96 | 2019 | Effects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis | Lousin Moumdjian; FEYS, Peter; Paul van Asch; Veronica Popescu; Bart Van Wijmeersch; Bert Opt' Eijnde; Inez Wens; Florian Van Haleweyck; Peter Feys; MOUMDJIAN, Lousin; VAN HALEWYCK, Florian; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; VAN ASCH, Paul | Journal Contribution | A1 |
| 97 | 2019 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 98 | 2019 | Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression | DE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y. | Journal Contribution | M |
| 99 | 2019 | Deciphering morphology of Evoked Potentials | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M.; Dive, D.; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 100 | 2019 | Therapeutic lag in relapsing multiple sclerosis | ROOSEN, Inge; Frascoli, F.; Horakova, D.; Havrdova, E. K.; Trojano, M.; Izquierdo, G.; Eichau, S.; Patti, F.; Onofr, M.; Lugaresi, A.; Prat, A.; Girard, M.; Duquette, P.; Ozakbas, S.; Grammond, P.; Sola, P.; Ferraro, D.; Bergamaschi, R.; Boz, C.; Cartechini, E.; Sa, M. J.; Terzi, M.; Alroughani, R.; Grand'Maison, F.; Granella, F.; Iuliano, G.; Hupperts, R.; Lechner-Scott, J.; Spitaleri, D.; Van Pesch, V.; Soysal, A.; Prevost, J.; Aguera-Morales, E.; Olascoaga, J.; Turkoglu, R.; Sidhom, Y.; Gouider, R.; VAN WIJMEERSCH, Bart; Butzkueven, H.; Malpas, C.; Kalincik, T. | Journal Contribution | M |
Loading...
5
0
5
0
false